NCT03079505View on ClinicalTrials.gov

Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia

PHASE3TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 3, 2017

Primary Completion Date

September 23, 2018

Study Completion Date

September 23, 2018

Conditions
Chronic Myeloid Leukemia - Chronic Phase
Interventions
DRUG

Dasatinib 100 MG [Sprycel]

Dasatinib (Sprycel) 100 milligram, once-daily (QD) will be given to 25 patients orally

DRUG

Nilotinib 150mg oral capsule [Tasigna]

Nilotinib (Tasigna) 300 milligram, twice-daily (BID) will be given to 25 patients orally

Trial Locations (1)

3050

National Center for Cancer Care & Research (NCCCR), Doha

Sponsors
All Listed Sponsors
lead

Hamad Medical Corporation

INDUSTRY